All In Biotech

Drug Trial Radar · NCT05298800

Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23

Clinical Observation of Combined Immunization of COVID-19 Inactivated Vaccine With Quadrivalent Influenza Vaccine(QIV) and 23-valent Pneumococcal Polysaccharide Vaccine

Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,000

Planned (sponsor's estimate)

Start

Oct 8, 2021

Primary completion

Dec 31, 2022

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Centers for Disease Control and Prevention, ChinaGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide vaccine in people aged 18 years and older. A randomized controlled, open trial design was adopted. The study was conducted with informed consent of the subjects for immunogenicity and safety in the population aged 18 years and older. A total of 3000 healthy subjects were selected, (1)600 healthy subjects were selected for the immunogenicity and safety study of co-immunization, 300 in the adult group (18-59 years old) and 300 in the elderly group (60 years old and above); (2) 2400 healthy subjects were selected for the observational study of the safety of co-immunization, 1200 in the adult group (18-59 years old) and 1200 in the elderly group (60 years old and above ) 1200 people.

Conditions

  • Safety
  • Immunogenicity, Vaccine
  • COVID-19 Vaccines
  • Influenza Vaccines
  • Pneumococcal Vaccines

Interventions

  • VaccineBiological

    Different arms were administrated different vaccines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate of neutralizing antibodyTime frame: 28 days after the third dose of COVID-19 vaccine

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Daxing District Center of Disease Control and Prevention

    Beijing, China · Recruiting

  • Huairou District Center of Disease Control and Prevention

    Beijing, China · Recruiting

  • Miyun District Center of Disease Control and Prevention

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.